Lysosomal Therapeutics, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Lysosomal Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2019).
SEC Form D · Nov 2019
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2019
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Lysosomal Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Cornelis Been | Executive officer | Nov 2019 |
| Daniel Geffken | Executive officer | Nov 2019 |
| Robert Carpenter | Executive officer | Nov 2019 |
| Bruce L. Booth | Director | Nov 2019 |
| Carole E. Nuechterlein | Director | Nov 2019 |
| Clay E. Thorp | Director | Nov 2019 |
| Cornelis Been | Director | Nov 2019 |
| Robert Carpenter | Director | Nov 2019 |
| Steven E. Hall | Director | Nov 2019 |
| Bernard Davitian | Director | Jan 2017 |
| Bruce Booth | Director | Jan 2017 |
| Carole Neuchterlein | Director | Jan 2017 |
| Clay Thorp | Director | Jan 2017 |
| Steven Hall | Director | Jan 2017 |
| Carole Nuechterlein | Director | Oct 2016 |
| Dimitri Krainc | Director | May 2014 |
| Henri Termeer | Director | May 2014 |
| Peter Wirth | Director | May 2014 |